MAG Unveils Its First A330neo, Ushering in a New Era of Air Travel

KUALA LUMPUR, Malaysia, Dec. 24, 2024 /PRNewswire/ -- Malaysia Aviation Group (MAG), the parent company of national carrier Malaysia Airlines, proudly commemorated the arrival of its first A330-900 (A330neo) aircraft today with a launch ceremony held at Hangar 6, MAB Engineering Complex. This milestone marks a pivotal step in MAG's fleet modernisation strategy as it strengthens its commitment to enhancing operational efficiency and providing passengers with an elevated level of comfort and service.

The aircraft, registered as 9M-MNG, was officially launched by Loke Siew Fook, Minister of Transport Malaysia, together with Dato' Amirul Feisal Wan Zahir, Managing Director of Khazanah Nasional Berhad, MAG's main shareholder; and Datuk Captain Izham Ismail, Group Managing Director of MAG. The aircraft will embark on its maiden flight to Melbourne via flight MH149 later this evening at 10:30pm local time and will gradually service long-haul routes across Australasia, among others.  

YB Loke Siew Fook, Minister of Transport Malaysia said, "The launch of MAG's first Airbus A330neo is not simply the introduction of a new aircraft; it is the culmination of resilience, determination, and an unwavering belief in the power of progress.

It reflects MAG's determination to lead in a competitive industry, our nation's commitment to sustainability, and the extraordinary potential of Malaysian talent."

Datuk Captain Izham Ismail, Group Managing Director of Malaysia Aviation Group (MAG), said, "The debut of our first A330neo marks a transformative moment for MAG as we modernise our fleet and set a new era of air travel where innovation, comfort, and sustainability come together seamlessly. This commitment underscores our dedication to placing our passengers at the heart of everything we do, delivering an exceptional and unforgettable journey that embodies the warmth and care of Malaysian Hospitality."

The A330neo is the latest aircraft to join MAG's growing fleet, with a total of 20 to be delivered by 2028 following its Memorandum of Understandings (MOU) with Airbus, Rolls-Royce and Avolon in August 2022. Powered by the Rolls-Royce Trent 7000 engines, the A330neo features the latest innovations in aerodynamics, advanced materials, delivering a 14% reduction in fuel consumption and carbon emissions compared to previous-generation aircraft. 

MAG's A330neo aircraft comprises 297 seats (28 in Business Class and 269 in Economy Class, of which 24 seats come with extra legroom). With a 1-2-1 herringbone configuration, the newly designed Collins Aerospace Elevation Business Class seats will be a first for the Group, featuring an all-suite cabin with individual privacy doors which prioritises cabin comfort and practicality. 

The new A330neo aircraft is set to elevate the travel experience with a host of advanced features, including the industry–leading FlightPath3D moving map system — the most interactive across all MAG fleet – offering real-time tracking and detailed journey insights, enhancing the way passengers explore the skies. In keeping with the airline's family-friendly approach, the aircraft's in-flight entertainment system will also come with 'Kids Mode', providing a seamless interface in keeping them entertained throughout their journey. 

Passengers can also enjoy a comprehensive destination guide that highlights the culture and history of the destinations served by the aircraft. Additionally, the aircraft will come with high-speed connectivity, allowing all passengers, regardless of cabin class or loyalty tier, to enjoy complimentary Wi-Fi onboard. In addition, Business Class passengers can also indulge in the SkySnacks offering, a selfservice concept featuring a curated selection of light snacks to munch at any time. 

At the same event, Malaysia Airlines unveiled an exclusive partnership with Mercedes-Benz as its private terminal transfer service provider starting January 2025. Eligible passengers will enjoy travelling in premium comfort and will be chauffeured in style in the all-electric Mercedes-Benz EQS 500 4MATIC and Mercedes-Benz S 580 e plug-in hybrid – that deliver quiet, dynamic and luxurious experience, making them the perfect choice for this exclusive service, where sustainability and sophistication converge seamlessly. The airline is the only carrier to introduce this private transfer service in KLIA Terminal 1 between the Main Terminal Building and Satellite Building as part of its commitment to elevating the passenger experience. 

MAG currently operates a fleet of 107 aircraft across its subsidiaries, including Malaysia Airlines, Firefly, MASwings and MASkargo. Looking ahead, the Group plans to expand its fleet to 62 narrowbody and 52 widebody aircraft by 2033. Its fifth Boeing 737-8 aircraft was delivered mid-December, with the remaining 20 expected between 2025-2026. 

Campaign link: https://www.malaysiaairlines.com/my/en/plan-trip/destinations/flights-to-australia/flights-to-melbourne.html?cid=pr|MY1224A330NEO|pr_newswire|tactical|art|pros|hk|a330neo|zh|campaign|mab|awa 

Campaign Video on Youtube: https://youtu.be/81ynJ6eoaLE 

ENDS

About Malaysia Aviation Group  

Malaysia Aviation Group (MAG) is a global aviation organisation comprising three focused business portfolios from Airlines, Loyalty and Travel Services (LTS) and Aviation Services.  

Its current Airlines business portfolio that serves the global, domestic and segmented market comprises Malaysia Airlines – the national carrier of Malaysia, Firefly and MASwings – the regional airlines focused on serving communities across Malaysia, and AMAL by Malaysia Airlines – leading one-stop pilgrimage travel solutions centre.  

MAG also focuses on Aviation Services business such as maintenance, repair and overhaul (MRO), cargo, ground handling and training that houses MAB Engineering, MASkargo – one-stop cargo logistic and terminal operations service provider, AeroDarat – one-stop ground handling solution provider and Malaysia Airlines Academy – onestop Aviation and Hospitality Centre of Excellence.  

The Loyalty and Travel Services (LTS) business portfolio focuses on providing end-to-end travel solutions and loyalty programs, complementing its established strength and expertise in the airline and aviation service businesses. It comprises Journify - the integrated one-stop travel and lifestyle digital platform, Enrich – the award-winning Travel & Lifestyle Loyalty Programme of Malaysia Airlines; and MHholidays and Firefly Holidays – the tour operating arm for the Group.   

With the clear business portfolios, MAG is set to achieve its vision anchored on becoming Asia's Leading Travel and Aviation Services Group, focused on delivering highly customised, end-to-end travel solutions by 2025.  

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

MAG Unveils Its First A330neo, Ushering in a New Era of Air Travel

MAG Unveils Its First A330neo, Ushering in a New Era of Air Travel

HEIDELBERG, Germany, Dec. 25, 2024 /PRNewswire/ -- European Wellness Biomedical Group (EWBG) has launched a new research initiative focused on Klotho, a protein with transformative potential in longevity medicine. Led by Professor Dr. Mike Chan, this project will explore Klotho's role in combating age-related diseases and its ability to regenerate critical organs, including the brain, kidneys, and heart.

Klotho, identified in 1997, is emerging as a key protein in longevity and regenerative medicine. It plays a pivotal role in regulating oxidative stress, mineral metabolism, and inflammation. The research will investigate how boosting Klotho levels could help address chronic conditions like neurodegenerative diseases, kidney failure, and heart disease, ultimately improving healthspan and extending lifespan.

"Klotho represents the next frontier in longevity medicine," said Professor Mike Chan, Chief Scientist at EWBG. "Our research aims to understand how Klotho affects aging and how we can use it to treat chronic diseases that have long been associated with aging."

Research Focus Areas

The new initiative will focus on three primary research areas:

This research builds on existing collaborations at EWBG, where leading scientists focus on advancing Klotho-based therapies for regenerative health.

Klotho: A Potential Breakthrough in Longevity Medicine

Klotho is gaining attention for its ability to regenerate tissues and reverse damage caused by age-related diseases. Unlike NAD+, which primarily enhances cellular metabolism and energy production, Klotho offers a broader range of therapeutic applications, including tissue regeneration, cognitive function improvement, and cardiovascular health.

As we age, Klotho levels naturally decline, leading to conditions such as cognitive decline, heart disease, and kidney failure. Research suggests that restoring Klotho levels can reverse the effects of oxidative stress, inflammation, and cellular senescence, offering new treatment possibilities for a range of age-related diseases.

Professor Mike Chan: Leading the Charge in Klotho Research

Professor Mike Chan, a leading expert in stem cell therapy and longevity medicine, is spearheading this groundbreaking initiative at EWBG. His extensive experience in bio-regenerative medicine positions him as a key figure in exploring Klotho's potential to revolutionize the treatment of age-related diseases. Through FCTI, a subsidiary of EWBG, Professor Chan and his team are developing therapies that combine stem cell technology and Klotho proteins to stimulate tissue regeneration in the brain, kidneys, and heart.

"By harnessing Klotho's regenerative properties, we hope to address chronic conditions that were previously untreatable," said Professor Chan. "Our ultimate goal is to improve quality of life and provide lasting solutions for those affected by aging-related diseases."

The Future of Klotho in Longevity Medicine

The future of Klotho-based therapies looks promising, with Professor Mike Chan and EWBG at the forefront of this innovative field. As more research is conducted, Klotho is expected to play a pivotal role in advancing longevity medicine, offering a new approach to treating aging and chronic diseases. The potential applications of Klotho are vast, from neurodegenerative disease treatment to kidney regeneration and cardiovascular health.

With strong research partnerships, significant funding, and ongoing clinical trials, Klotho is poised to become a cornerstone of longevity medicine, transforming how we approach aging and disease. Professor Mike Chan's leadership ensures that this promising protein will soon offer new hope to those seeking longer, healthier lives.

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

European Wellness Biomedical Group Announces New Klotho Research Initiative Led by Prof. Mike Chan